MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

← catalyst calendar

NCT06980506

Sponsored by Monopar Therapeutics (industry) · MNPR — their whole pipeline →.

Phase

—

Status

Temporarily not available

Study type

Expanded access

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-09-04

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

—

When the study began enrolling

Primary completion

—

The date the last participant is measured for the primary outcome — the readout window

Study completion

—

The whole study's end, after follow-up

First posted

2025-05-20

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-09-04

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Cancer
Solid Tumor
Solid Tumor, Adult

Intervention

Diagnostic test: MNPR-101-DFO*-89Zr

MNPR · their whole pipeline · Solid Tumors readouts

MNPR's other studiesmost recently updated first

MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer — · Temporarily not available
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors Phase 1 · Active, not recruiting
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors Phase 1 · Active, not recruiting
Camsirubicin + Pegfilgrastim to Determine MTD in ASTS Phase 1 · Terminated
Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. Phase 2/3 · Terminated

Permalink · MNPR's whole pipeline · Catalyst calendar · Every registered study · What changed